Recent Advances in the Treatment of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a disease in which stenosis or obstruction of the pulmonary arteries (PAs) causes an increase in PA pressure, leading to right-sided heart failure and death. Basic research has revealed a decrease in the levels of endogenous vasodilators, such as prostacyclin...

Descripción completa

Detalles Bibliográficos
Autores principales: Otani, Naoyuki, Tomoe, Takashi, Kawabe, Atsuhiko, Sugiyama, Takushi, Horie, Yasuto, Sugimura, Hiroyuki, Yasu, Takanori, Nakamoto, Takaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609229/
https://www.ncbi.nlm.nih.gov/pubmed/36297387
http://dx.doi.org/10.3390/ph15101277
_version_ 1784818967658889216
author Otani, Naoyuki
Tomoe, Takashi
Kawabe, Atsuhiko
Sugiyama, Takushi
Horie, Yasuto
Sugimura, Hiroyuki
Yasu, Takanori
Nakamoto, Takaaki
author_facet Otani, Naoyuki
Tomoe, Takashi
Kawabe, Atsuhiko
Sugiyama, Takushi
Horie, Yasuto
Sugimura, Hiroyuki
Yasu, Takanori
Nakamoto, Takaaki
author_sort Otani, Naoyuki
collection PubMed
description Pulmonary arterial hypertension (PAH) is a disease in which stenosis or obstruction of the pulmonary arteries (PAs) causes an increase in PA pressure, leading to right-sided heart failure and death. Basic research has revealed a decrease in the levels of endogenous vasodilators, such as prostacyclin, and an increase in the levels of endogenous vasoconstrictors, such as endothelin, in patients with PAH, leading to the development of therapeutic agents. Currently, therapeutic agents for PAH target three pathways that are selective for PAs: the prostacyclin, endothelin, and nitric oxide pathways. These treatments improve the prognosis of PAH patients. In this review, we introduce new drug therapies and provide an overview of the current therapeutic agents.
format Online
Article
Text
id pubmed-9609229
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96092292022-10-28 Recent Advances in the Treatment of Pulmonary Arterial Hypertension Otani, Naoyuki Tomoe, Takashi Kawabe, Atsuhiko Sugiyama, Takushi Horie, Yasuto Sugimura, Hiroyuki Yasu, Takanori Nakamoto, Takaaki Pharmaceuticals (Basel) Review Pulmonary arterial hypertension (PAH) is a disease in which stenosis or obstruction of the pulmonary arteries (PAs) causes an increase in PA pressure, leading to right-sided heart failure and death. Basic research has revealed a decrease in the levels of endogenous vasodilators, such as prostacyclin, and an increase in the levels of endogenous vasoconstrictors, such as endothelin, in patients with PAH, leading to the development of therapeutic agents. Currently, therapeutic agents for PAH target three pathways that are selective for PAs: the prostacyclin, endothelin, and nitric oxide pathways. These treatments improve the prognosis of PAH patients. In this review, we introduce new drug therapies and provide an overview of the current therapeutic agents. MDPI 2022-10-17 /pmc/articles/PMC9609229/ /pubmed/36297387 http://dx.doi.org/10.3390/ph15101277 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Otani, Naoyuki
Tomoe, Takashi
Kawabe, Atsuhiko
Sugiyama, Takushi
Horie, Yasuto
Sugimura, Hiroyuki
Yasu, Takanori
Nakamoto, Takaaki
Recent Advances in the Treatment of Pulmonary Arterial Hypertension
title Recent Advances in the Treatment of Pulmonary Arterial Hypertension
title_full Recent Advances in the Treatment of Pulmonary Arterial Hypertension
title_fullStr Recent Advances in the Treatment of Pulmonary Arterial Hypertension
title_full_unstemmed Recent Advances in the Treatment of Pulmonary Arterial Hypertension
title_short Recent Advances in the Treatment of Pulmonary Arterial Hypertension
title_sort recent advances in the treatment of pulmonary arterial hypertension
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609229/
https://www.ncbi.nlm.nih.gov/pubmed/36297387
http://dx.doi.org/10.3390/ph15101277
work_keys_str_mv AT otaninaoyuki recentadvancesinthetreatmentofpulmonaryarterialhypertension
AT tomoetakashi recentadvancesinthetreatmentofpulmonaryarterialhypertension
AT kawabeatsuhiko recentadvancesinthetreatmentofpulmonaryarterialhypertension
AT sugiyamatakushi recentadvancesinthetreatmentofpulmonaryarterialhypertension
AT horieyasuto recentadvancesinthetreatmentofpulmonaryarterialhypertension
AT sugimurahiroyuki recentadvancesinthetreatmentofpulmonaryarterialhypertension
AT yasutakanori recentadvancesinthetreatmentofpulmonaryarterialhypertension
AT nakamototakaaki recentadvancesinthetreatmentofpulmonaryarterialhypertension

Ejemplares similares